X4 Pharmaceuticals, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 3.36 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 333.13M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Details
| Name | X4 Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 45 |
| Founded | 2014 |
| Ceo | Paula Ragan |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US98420X2027 |
| Cusip | 98420X202 |
| Cik | 1501697 |
| Sic | 2836 |
Key executives
| Name | Title |
|---|---|
| Dr. Adam R. Craig M.B.A., M.D., Ph.D. | Executive Chair |
| John P. Volpone M.B.A. | President and Chief Operating Officer |
| David H. Kirske | Chief Financial Officer, Treasurer and Corporate Secretary |
| Dr. Richard Peters M.D., Ph.D. | Founder |
| Dr. Renato T. Skerlj Ph.D. | Founder |
| Dr. Keith T. Flaherty M.D. | Founder and Member of Corporate Advisory Board |
Contact
| Address | 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134, United States |
| Phone | 857 529 8300 |
| Website | https://www.x4pharma.com |